Mitochondrial Protection Prevents Chronic Muscle Weakness After Sepsis

Sepsis, a life-threatening condition caused by the body's overwhelming response to infection, often leads to severe and persistent muscle weakness in survivors, significantly impacting their quality of life. This long-term debility is thought to involve mitochondrial dysfunction (when mitochondria, the cell's powerhouses, don't work correctly) within muscle cells. This study specifically addresses the potential of pharmacological interventions to protect mitochondria and prevent this chronic post-sepsis muscle weakness.

Untreated septic mice exhibited a significant decline in muscle function, showing a 45% reduction in grip strength compared to sham controls at 14 days post-sepsis. In stark contrast, mice treated with Mito-Protector demonstrated remarkable preservation of muscle strength, with only a 12% reduction compared to sham, indicating a 73% improvement over untreated septic animals. Furthermore, mitochondrial respiration rates in muscle tissue were 2.8-fold higher in the Mito-Protector group compared to the untreated septic group, alongside a 35% reduction in markers of oxidative stress. The most impactful finding was that pharmacological protection of mitochondria with Mito-Protector effectively prevented 73% of the chronic muscle strength loss observed after sepsis, with a statistical significance of p<0.001.